CCRL1 antibody (PE)

Catalog No. ABIN2662413

The PE-conjugated Mouse Monoclonal anti-CCRL1 antibody (Clone 13E11) (ABIN2662413) specifically detects CCRL1 in FACS. The antibody is reactive with Human samples.

Quick Overview for CCRL1 antibody (PE) (ABIN2662413)

Target: CCRL1 (Chemokine (C-C Motif) Receptor-Like 1 (CCRL1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CCRL1 antibody is conjugated to PE

Application: Flow Cytometry (FACS)

Clone: 13E11

Product Details anti-CCRL1 Antibody (PE)

Purification: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG2b kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CCRL1

Target: CCRL1 (Chemokine (C-C Motif) Receptor-Like 1 (CCRL1))

Alternative Name: CCX-CKR

Background: Human CCX-CKR, also known as CCRL1, is a 40 kD, G-protein-coupled, seven transmembrane receptor. CCRL1 is a decoy receptor for CCL2, CCL8, CCL13, CCL19, CCL21 and CCL25 that regulates chemotaxis of lymphocytes and cancer cells. Chemokine binding by CCX-CKR causes its internalization, reducing levels of available chemokine, and thus regulating migration of lymphocytes and cancerous cells. CCX-CKR is expressed by stromal cells of skin-draining lymph nodes, thymic epithelial cells, and immature dendritic cells (DCs). A low CCX-CKR expression in tumor cells correlates with a poor survival rate of breast cancer patients.